Table 3:

Outcomes related to pre-HSCT MRD status by flow cytometry using ΔN approach

	Absence (N = 113) ‡		Presence (N = 10) ‡
Outcomes	N Eval	Prob (95% CI)	N Eval	Prob (95% CI)	p-value
Transplant-related mortality	113		10		0.43
Day 100		6 (3–11)%		20 (2–49)%	0.22
6 months		12 (7–19)%		20 (2–49)%	0.47
1-year		14 (8–21)%		20 (2–49)%	0.56
2-year*		14 (8–21)%		20 (2–49)%	0.56
Relapse incidence	113		10		0.03
Day 100		14 (8–21)%		30 (7–60)%	0.29
6 months		24 (17–32)%		40 (13–70)%	0.37
1-year		29 (21–38)%		50 (21–79)%	0.25
2-year*		32 (23–40)%		70 (40–93)%	0.01
Disease free survival	113		10		0.002
Day 100		81 (74–88)%		50 (21–79)%	0.05
6 months		64 (55–72)%		40 (13–70)%	0.14
1-year		57 (47–66)%		30 (7–60)%	0.08
2-year*		55 (46–64)%		10 (0–35)%	<0.001
Overall survival	113		10		0.001
Day 100		91 (85–96)%		80 (51–98)%	0.39
6 months		77 (69–84)%		70 (40–93)%	0.64
1-year		69 (60–77)%		30 (7–60)%	0.010
2-year*		63 (54–72)%		20 (2–49)%	0.001

^*2 year: 2 patients lost to follow up

^‡Excludes patients without pre-HSCT BM MRD assessment, 86/123 specimens were classified as adequate at the time of analysis.